The observed need for combining AGX51 treatment with chemotherapy to see anti-tumor efficacy in established mammary fat pad and lung tumors reflects the situation seen in genetic analyses where Her2/neu breast tumor regression required chemotherapy in Id knockout mice59. This evidence concerns the gene ERBB2 and neoplasm.